Detalles de la búsqueda
1.
The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
J Pharmacol Exp Ther
; 351(3): 538-48, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25253883
2.
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Am J Hematol
; 94(4): E90-E93, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30592080
3.
An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin.
J Clin Invest
; 134(4)2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38357917
4.
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
J Pharmacol Exp Ther
; 344(2): 378-87, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23220742
5.
SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Blood
; 118(24): 6342-52, 2011 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-22025527
6.
Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
J Pharmacol Exp Ther
; 340(2): 350-9, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22040680
7.
Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin.
J Cell Sci
; 122(Pt 17): 3137-44, 2009 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19654214
8.
Cutting edge: The transmembrane E3 ligase GRAIL ubiquitinates the costimulatory molecule CD40 ligand during the induction of T cell anergy.
J Immunol
; 181(3): 1622-6, 2008 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18641297
9.
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Clin Cancer Res
; 25(4): 1174-1184, 2019 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30333224
10.
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.
Oncotarget
; 8(8): 12953-12967, 2017 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28088788
11.
PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers.
J Clin Pharmacol
; 57(2): 194-210, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27406873
12.
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
Clin Cancer Res
; 23(9): 2313-2324, 2017 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27697994
13.
Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
Oncotarget
; 6(41): 43881-96, 2015 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26575169
14.
Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior.
Neuropsychopharmacology
; 29(8): 1479-87, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15100700
15.
Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis.
Pharmacol Res Perspect
; 1(2): e00016, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25505569
16.
Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice.
Drug Metab Dispos
; 33(5): 623-9, 2005 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15673599
Resultados
1 -
16
de 16
1
Próxima >
>>